• Compliant, protective, and blast-proof products can reduce damage at federal, state, and local facilities
• Barriers, revetments, fuel tank jackets, and blast protection equipment are suitable for customers in commercial and military market sectors
• New products or retrofits are available to customers requiring powerful blast protection and fire suppression systems

Blastgard International, Inc. (OTC: BLGA) is a manufacturer of proprietary blast mitigation products that meet the requirements of the Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act). Used by commercial, law enforcement, government, and military customers, the company’s blast-resistant and fire-suppressing materials provide the anti-terrorism protection specified under the Department of Homeland Security’s SAFETY Act. The legislation calls for technology that can be immediately deployed at public and private facilities, limit liability of anti-terrorism technology providers, and prevent a large-scale loss of life and economic impacts.

In addition, Blastgard’s products have been approved by the General Services Administration (GSA). This qualification streamlines procurement in that several federally-mandated contracting requirements are met. Being approved by the GSA means products such as BlastWrap® are differentiated in the market, so public and private agencies can have improved access to them. BlastWrap is on the DHS’s “Approved Products List for Homeland Security” and provides protection against strong explosions, ballistic materials, and fragments. Working indoors and outdoors, in wet/dry conditions and vented/unvented locations, it can protect property and people against solid explosives and fires caused by flammable liquids.

BlastWrap materials can be used in the cargo holds and containers of commercial aircraft, as building walls (to protect against vehicle bombs), and around fuel tanks to suppress explosions and fireballs. They have also been used on naval vessels and merchant ships, minimizing the impact from mines, torpedoes, and cruise missiles. Suitable as dividers on aircraft, ships, and offshore platforms to suppress fuel mist explosions and fireballs, the products have also been used in explosives manufacturing and handling facilities, propellant manufacturing plants, and fireworks plants as partitions and separators. Also, the company’s products have been implemented in underwater applications and entertainment industry sound stages.

The company also manufactures the Blastgard MTR Series of trash receptacles. These triple-wall containers can withstand improvised explosive devices, their fragments, and fires. Weatherproof and corrosion-resistant, the 35-gallon capacity receptacles can be customized with colors, artwork, logos, and powder coating. Each unit can resist over 4,000 pounds of horizontal and vertical force.

Usable in just about any industry, Blastgard’s products are in demand at a time when terror attacks occur on a regular basis. Recent events in Europe, including a bomb explosion at the Brussels Central train station on June 20 (http://dtn.fm/Rlxb8), warrant methods of protecting personnel and civilians with equipment that can withstand explosions and fires. The incident occurred just months after terror attacks killed over 30 people in the city. Additional events and heightened alerts demonstrate the need for protection when such potentially devastating incidents cannot be avoided.

For more information about BlastGard International, BlastWrap technology, and blast-proof products for commercial, military, law enforcement, and government segments, go to www.BlastgardIntl.com

Let us hear your thoughts: BlastGard International, Inc. Message Board

• Alzheimer’s is the most ominous and expensive disease in the U.S.
• IGC is the first and only NYSE MKT-listed pharmaceutical company to develop cannabis-based Alzheimer’s therapies
• IGC’s patent pending phytocannabinoid therapies to enter clinical trials for potential Alzheimer’s breakthrough

A pioneer in the development of innovative cannabis-based combination therapies, India Globalization Capital (NYSE MKT: IGC) is creating new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patent pending therapeutics include treatments for pain, cachexia, neurologic disorders, Parkinson’s and Alzheimer’s disease. IGC plans to enter clinical trials this year on its primary pipeline of four major therapeutics that address large market maladies. These trials include a potential cannabis-based blockbuster treatment for Alzheimer’s, America’s most ominous and expensive disease.

Alzheimer’s disease has no cure, no means of prevention and no long-term disease-modifying treatments. It’s a fatal, progressive brain disease that slowly destroys memory and thinking skills. It’s the third-leading cause of death in the U.S., following cancer and heart disease. More than 5.3 million Americans and over 46 million people worldwide are currently suffering from Alzheimer’s, and, frighteningly, this number is expected to triple within a few decades. Alzheimer’s is also the most expensive disease in the nation. In 2016, costs totaled $236 billion for the U.S., and global costs exceeded $600 billion. These figures will skyrocket if the disease continues unchecked.

Bolstering its portfolio of patent pending cannabis-based pharmaceuticals, IGC recently acquired exclusive rights to a novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). Under the definitive license agreement with the university, IGC is the exclusive licensee of a patent filing for the use of tetrahydrocannabinol (THC) as a potential therapeutic agent for Alzheimer’s. The patent claims discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.

This new pathway holds immense potential in treating Alzheimer’s, and IGC will own the rights to this unprecedented therapeutic pathway if the patent is granted and proven. Acquiring this patent further supports IGC in protecting its proprietary formulation IGC-AD1, which includes low-doses of THC and is intended to disrupt the buildup of amyloid beta plaques and alleviate some of the worst symptoms of Alzheimer’s disease.

Several clinical studies are currently underway to address the ravages of Alzheimer’s, but later this year IGC will become the first and only company to utilize cannabis-based therapies for the treatment of the disease. Even though there are about a dozen publicly traded cannabis pharmaceutical stocks on the market, none have patent filings to a potential Alzheimer’s breakthrough.

Should IGC’s clinical studies show promise on Alzheimer’s or any of its primary pipeline of phytocannabinoid therapeutics, it could not only trigger a major shift in national medical marijuana policy but also dramatically impact the company’s market capitalization and stock price to the upside.

For more information, please visit http://www.igcinc.us

• Canadian Cannabis Valuations up 200% in two years
• 250 acres of cultivation space stretching from Alberta to Ontario
• Paid out $1,000,000 in Dividends representing $0.07 per Share

It might just be that Invictus MD Strategies Corp. (OTC: IVITF) (TSX.V: IMH) (FRA: 8IS) has adopted as a motto the elevating penultimate line from William Ernest Henley’s immortal poem Invictus: “I am the master of my fate”. Canada’s Cannabis Company appears completely unafraid as it ploughs ahead with its strategy to become a dominant company in Canada’s cannabis space. That boldness is paying off; Invictus is one of only a handful of cannabis companies declaring dividends. Now, with 250 acres of cultivation space stretching from Alberta to Ontario under management, Invictus is poised to deliver product to Canada’s medical and recreational marijuana markets, as Ottawa reiterates its determination to implement a legal framework for adult use by July 2018 (http://dtn.fm/yQG0j).

In executing that market domination strategy, Invictus’s management has pulled off some savvy deals since the company went public, under the symbol IMH, on the Canadian Securities Exchange (CSE) in December 2014. In March 2015, Invictus took up a 20 percent stake in hydroponic service company Future Harvest Development (FHD). Just four months later, it quickly increased that investment to acquire a majority holding and then sold off FHD’s Sunblaster Lighting division in February 2016. Those breathtaking developments provided a 216% return on investment; Sunblaster, sold for $2,850,000, had an acquisition cost of $900,000. Invictus now holds 82.5% of FHD.

Cannabis Health Sciences was another successful exit. The company, which publishes the Cannabis Health Journal, was bought for $45,000 and later sold for $230,000, earning Invictus a hefty return of 411 percent.

Invictus’ current portfolio companies have equal potential. Wholly-owned Acreage Farms of West-Central Alberta is currently valued at $34.5 million. The division received its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on March 29, 2017, and is already operational. A 6,800 sq ft purpose built concrete and steel facility has already been constructed, and a planned expansion of 27,400 sq ft on the 150-acre property is imminent. Cultivation started in May 2017, and the unit is expected to reach output of 3,000 kg in 2018, 10,000 kg in 2019 and 25,000 kg by 2020.

In addition, together, associated companies AB Laboratories and AB Ventures are likely to do even better. Their joint production capacity is planned, by 2018, to hit 5,000 kg before climbing to 15,000 kg in 2019 and a level of 25,000 kg in 2020. AB Laboratories already has a cultivation license, received on October 21, 2016. The company, in which Invictus has a one-third stake, expects to get its sales license very soon and is currently valued at $30 million. Its facility in Hamilton, Ontario, covers about 16,000 sq ft.

AB Ventures is Invictus’s “startup” operation. The division closed a 100-acre acquisition in May 2017 and has filed an ACMPR pre-license application for that planned facility. It is aiming to develop 100,000 sq ft (about 2¼ acres) of cultivation and production space by 2019. The unit, in which Invictus also has a one-third stake, is valued at $22.5 million.

There is no doubt that halcyon days are ahead for Invictus. Valuations of cannabis companies have risen over 200 percent over the past two years, with some high fliers crossing the 300% mark. Valuations of ancillary businesses, those that supply services and equipment to the cannabis industry, are rising on the swell, too. Invictus was able to pay out a $1 million dividend to shareholders on December 5, 2016, representing $0.07 per share, because of its divestment of Sunblaster Lighting. With the Canadian recreational cannabis market projected to reach $6 billion, Invictus, now listed on the TSX-V under the symbol IMH, has a fate that looks decidedly promising.

For more information, please visit www.Invictus-MD.com

• Unique proprietary technology meeting growing and compelling global need
• HighCom Security division is the first company in the world to achieve BA 9000 certification
• Strong connections and sales history with DOD and DHS, as well as with law enforcement and commercial entities around the world

The rising incidence of terrorist attacks around the world is not being taken lying down. America’s police departments have taken note and are gearing up, literally, to defend the homeland. To do so, to protect their officers, they are relying increasingly on body armor and blast protection products, like those from BlastGard International, Inc. (OTC: BLGA). The Florida-headquartered company has developed a line of products to protect people and property from explosive blasts. It also provides products that offer protection from projectiles. BlastGard’s protective gear includes shields, helmets, vests and plates, which provide police with the protective gear they need to do their jobs.

With an estimated 750,000 police officers, America’s 17,000 law enforcement agencies require a lot of body armor, which, typically, has a life cycle of about five years. Combining this statistic with an average 10 percent attrition rate in law enforcement (about one in 10 officers leave every year) means that, every year, approximately 30 percent of body armor purchases are repeated. That results in a steady, vibrant market for BlastGard. In July 2014, its HighCom Security division, responsible for body armor, became the first company in the world to achieve BA 9000 certification. BA 9000, released in January 2012, extends ISO 9001 requirements to manufacturers of body armor vests for federal, state, local, tribal law enforcement and corrections bodies.

BlastGard’s HighCom Security business unit is a leader in advanced ballistic armor manufacturing. Operating from a 32,865 square foot manufacturing and distribution facility located in Columbus, Ohio, the division can handle large scale, time-sensitive global supply needs. Directed from the logistics center in Florida, the unit serves customers in North America, such as the Department of Defense and the Department of Homeland Security, local law enforcement agencies, correctional facilities, municipal authorities and large corporations, as well as others throughout the world. Past sales have been to Asia, Africa, Europe, Latin America, and the Middle East.

BlastGard’s body armor range is wide. It includes Type IIA body armor, which offers basic protection against smaller caliber handgun threats; Type II body armor, which provides protection against larger handguns, including many common smaller caliber pistols with standard pressure ammunition and against many revolvers; Type IIIA body armor, which can resist heavy pistol calibers including most law enforcement ammunition and many higher powered revolvers, and Type III and IV body armor, which provides protection against rifle rounds, generally only used in tactical situations.

BlastGard expects that, as police departments become more militarized, demand for its products and services will grow. As threats of all kinds multiply, there is mounting evidence of the emergence of a new kind of police officer, the Warrior Cop, resulting from the integration of tactical, SWAT, and special operations within the law enforcement environment. This trend is likely to fuel demand for body armor with higher protection levels and lower areal densities and designs that provide more mobility and comfort, including helmets. Areal density gives an indication of the energy absorption capability of the protective material and is computed as the weight of the armored panel in grams per square meter divided by the protection area of the panel.

The BlastGard Defense division offers BlastWrap®, a product that defuses the power of explosions and helps to suppress any fires caused by those explosions. The technology is composed of two integrated flexible films arranged one over the other and joined by a plurality of seams filled with attenuating filler material (volcanic glass bead or other suitable materials) with an extinguishing coating. It works by slowing the dissipation of energy triggered by an explosion, reducing the force of the blast and, consequently, the likelihood of fatalities. BlastGard is not only in the business of providing protection for individuals and property; it’s also in the business of saving lives.

For more information, visit the company’s website at www.BlastGardIntl.com

Let us hear your thoughts: BlastGard International, Inc. Message Board

• China’s economy is now world’s 2nd largest – set to overtake the U.S. this century
• 695 million+ mobile internet users create new Chinese consumer
• Moxian, Inc. (NASDAQ: MOXC) platforms convert online users to retail customers

The roots of modern capitalist China are curiously and inexorably linked to the 1949 foundation of the People’s Republic of China by communist revolutionary Mao Zedong. In spite of horrific atrocities, Mao is still credited for modernizing China and building it into a world power as China’s population grew from around 550 million to over 900 million under his leadership. Mao seized control of China after a brutal civil war and held power until his death in 1976. Many of his socialist policies such as promoting the status of women, improving education and health care, and increasing life expectancy actually integrate and underpin today’s Chinese economic model. Since inception, the People’s Republic of China has surreptitiously and steadily embraced the tenets of capitalism, especially since economic reforms were enacted in 1978.

Succeeding Mao, Deng Xiaoping, a Communist Party veteran, was eager to adopt capitalist methods and reforms to try to stimulate economic growth and restore confidence in the party. Deng launched several economic reforms that allowed private sectors to start and operate their own businesses again. He also established four special economic zones along the coast of China with intentions of attracting foreign investments. Due to the reforms Deng put in place, China has gone from being a country that opposed capitalism to one that embraces property rights, profits and free market competition.

Today, China’s economy is the second-largest in the world and is likely to overtake the U.S. sometime this century. The country is in the process of transforming itself from a global center of low-tech manufacturing into a major hub of innovation and consumption.

Computer usage in China has exploded. There are now over 730 million internet users in China and over 95 percent, 695 million+, use mobile devices for internet access. This massive increase of computer users in China creates both challenges and opportunities.

To capture the immense new opportunities in China’s changing consumer market, companies must become more strategic in targeting income segments, product categories, and retail channels. To succeed, it’s imperative that companies take into account rapid shifts in consumer consumption patterns. Serving the businesses that feed Chinese consumer demand, Moxian, Inc. (NASDAQ: MOXC) is poised to profit from the long and vast economic transition in China.

Moxian provides small and medium-sized businesses cutting edge turnkey solutions to attract and maintain customers. The company’s strategy is to drive consumer traffic from online to brick and mortar business customers. Moxian operates a captivating social network which integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged, coming back and even referring new customers.

The company’s online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both existing and new customers. These interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platform gives businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients give businesses the ability to study consumer behavior and tailor offerings to customers. Moxian is leveraging technology to drive business in the new Chinese consumer economy and offers an opportunity to profit from China’s transformation from communism to consumerism.

For more information, visit www.Moxian.com

The medical efficacy of cannabinoids to treat a multiplicity of maladies is no longer in doubt. Two recently published scientific studies dispelled any apprehensions about cannabis-based therapies. The highly respected New England Journal of Medicine published a peer reviewed article that proved in a controlled study that cannabidiol dramatically reduced the number of convulsive seizures in children stricken with a severe epileptic disorder (http://dtn.fm/hUy56). The results of this study follow a comprehensive report by the National Academies of Science, Engineering, and Medicine which confirmed that cannabinoids are effective at treating chronic pain and for providing relief from nausea and vomiting related to chemo treatments. Multiple other medicinal marijuana therapies are undergoing scientific review, including two potential blockbuster therapies in development by InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) for glaucoma and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity.

Utilizing its proprietary bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. Using comprehensive algorithms and extensive databases, the company’s exclusive computer-based program can scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s unique bioinformatics assessment tool holds significant promise for a profusion of future drug discoveries.

InMed is also developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This proprietary process will provide pharmaceutical consistency and reliability required for drug accuracy, efficacy, and safety.

With areas of research in dermatology, ocular indications, pain and inflammation, central nervous system disorders, and respiratory and metabolic diseases, InMed’s current pipeline is targeting unmet medical conditions utilizing disease-specific formulations. InMed’s INM-750 may become the first therapy to modulate disease activity and alleviate symptoms of epidermolysis bullosa, an orphan disease with no approved treatments and significant unmet medical need. InMed’s INM-085 glaucoma treatment is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy in treating one of the leading causes of blindness in the developed world.

InMed’s proprietary bioinformatics drug and disease screening tool, coupled with the company’s proprietary cannabinoid manufacturing system, will provide the unique ability to rapidly produce exceptional targeted results with expedited and cost effective drug development timelines.

The company’s systems and future hold such promise that Dr. Ado Muhammed, MD, DPM, MFPM, who was instrumental in leading GW Pharmaceuticals (NASDAQ: GWPH) through development and approval of one of the world’s first cannabis-based drugs, is now chief medical officer for InMed Pharmaceuticals. GW Pharmaceuticals saw its shares rise from less than $9 in 2013 to more than $100 today, and it now has a market value of more than $2.5B. With all the upside opportunity, a share price of only 30 cents and a market cap of about $34 million, InMed seems to be a real opportunity to profit from what may become the next success story in the ongoing quest to cure and mitigate disease with cannabinoid-based therapeutics.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

BlastGard International, Inc. (OTC: BLGA) manufactures proprietary blast mitigation products for the military, commercial sector, government agencies, and law enforcement. It also provides products in the Blastgard MTR Series for personal protective gear and offers products such as mitigated trash receptacles.

The company is doing business as BlastGard Defense Group and HighCom Security. It manufactures BlastWrap® technology proprietary blast materials to mitigate blast effects and post-blast fires. Its primary market focuses on clients operating in the military, commercial sector, government agencies, and law enforcement. It also offers personal protective gear through HighCom Security.

Industry applications for its technology products include suppressing fireballs and explosions. Its products are designed for naval vessels and merchant ships and to minimize damages from breaching blasts, and to protect buildings from vehicle bombs. BlastWrap has been named a Qualified Anti-Terrorism Technology and placed on the “Approved Products List For Homeland Security.” In January of 2017, the designation and certification for BlastWrap was extended until November 2021. The company’s products are also in the General Services Administration system.

The Blastgard MTR Series is a collection of triple-wall mitigated trash receptacles designed to reduce lethal threats from the detonation of an improvised explosive device, including primary and secondary fragments and any resultant post-blast fires. The products have triple-wall technology to achieve that ability to withstand explosions. This is a Colorado corporation operating out of offices in Clearwater, Florida, with a manufacturing facility in Columbus, Ohio. It generates 99% of sales from HighCom Securities, Inc.

Simultaneously, the company serves several different markets. As it serves the military and government agencies, it is also replacing existing technologies with products for commercial needs, including entertainment industry location sets (such as Hollywood sound stages), mining extracting and processing, building demolitions, and reinforcement of masonry buildings. Other markets include underwater blast isolation units, coastal construction, monitoring stations for law enforcement, and blast protection shields for low observable camouflage properties.

For more information, visit the company’s website at www.BlastGardIntl.com

Let us hear your thoughts: BlastGard International, Inc. Message Board

Furthering its efforts to innovate solutions for the cannabis industry, SinglePoint, Inc. (OTC: SING) has taken a step forward in its endeavor to offer a bitcoin payments solution for cannabis businesses through its partnership with First Bitcoin Capital Corp. (OTC: BITCF). SinglePoint recently announced (http://dtn.fm/Mq8ah) it has successfully closed a $1 million convertible promissory note with an institutional investor — the proceeds from which will be used to fund the company’s bitcoin payments endeavor and will enable SinglePoint to move quickly in developing a cryptocurrency solution and continuing its acquisitions activities in the cannabis space.

A lack of banking options for legalized marijuana businesses in the United States currently poses a significant obstacle for these cannabis enterprises, forcing them to conduct cash transactions because they do not have the cooperation of banks or the FDIC to accept credit and debit cards. Seeing bitcoin technology as a potential solution for this problem, SinglePoint recently partnered with First Bitcoin Capital to develop a proprietary bitcoin payment solution that can be implemented in any point-of-sale machine through an easy download and will allow customers to purchase cannabis products using debit and credit cards without the backing of banks or the FDIC.

Bitcoin is a digital currency that enables the transfer of funds in a way that is unregulated by governments and is conducted independent of banks. It is growing in popularity and even recently became an official payment method in Japan. As a potential solution for currently “unbankable” cannabis business, SinglePoint’s bitcoin solution is an exciting prospect.

Four developments have been planned by SinglePoint and First Bitcoin Capital based on bitcoin, ethereum and blockchain technology, and SinglePoint recently acquired the rights and domain name for www.SingleCoin.com as part of a planned potential initial coin offering (ICO), which would specifically support transactions for the marijuana industry and other high-risk industries.

In addition to its bitcoin payment solution development activities, SinglePoint has also created and is releasing a Web development and online marketing solution for cannabis dispensaries and plans to use some of the recent funding to launch a proprietary marketing system to attract new customers to SingleSeed.com, which has become a prime resource for dispensaries seeking merchant payment processing solutions and other business tools. SinglePoint offers payment solutions to cannabis businesses through SingleSeed payments, including mobile marketing and payment solutions such as Pay-by-Text™, cashless ATM and text message marketing.

Having made various acquisitions in its efforts to take a diversified approach in the cannabis industry without actually touching the plant, SinglePoint’s portfolio includes a majority stake in Discount Indoor Garden Supply, which immediately positioned the company to become a leader in online products, retail stores, cannabis consulting and equipment in California. The company additionally started funding Convectium in 2017. Convectium is a provider of equipment, branding and packaging solutions to the cannabis industry and is the developer of the first cartridge and vape pen oil-filling machines offered through wholesale distribution to cannabis dispensaries. Convectium’s 710Shark and 710Seal machines, currently sold through the EquipCanna.com website, are capable of filling and packaging more than 100 cartridges or disposable vape pens in 30 seconds. Convectium further operates a consumer brand that includes BlackoutX and HazeSticks products.

To listen to audio releases relating to the news, go to the following:

Audio version of release: http://dtn.fm/C2gRt

Follow-up discussion: http://dtn.fm/RGa9g

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

Converde Energy USA, Inc. (OTC: XFUL), d/b/a American Energy Partners Inc., has diversified its energy services portfolio following a successful rebranding effort. The Allentown, Pennsylvania-based company operates through various subsidiaries that have their own energy operations. Hydration Company of Pennsylvania (HCPA) focuses on water exploration and treatment with applications in multiple industries; American Energy Solutions (AES) is an industrial waste stream treatment company; and Gilbert Oil & Gas Company focuses more on generating value in the upstream gas and oil space through operating, drilling, and partnership opportunities. Overall, American Energy Partners hopes to significantly expand operations through involvement in hydrological projects and sourcing water supplies.

The ability to attract capital, form strategic alliances, and achieve sustained growth is helping American Energy Partners serve a diverse customer base. These assets are also attracting investors. Recently, it entered an agreement with GPL Ventures LLC, which may purchase stock valued at up to $3 million. Additionally, the company retained Minivest as a business advisor, to which it issued a Convertible Promissory Note valued at $100,000. Among other things, the agreement allowed access to Minivest’s online marketing platform to help XFUL strengthen its online advertising.

Competent subsidiaries are key contributors to the growth and success of XFUL. A technical workhorse, HCPA can source, implement, and distribute reclaimed water and work in a diversity of geographies, storage conditions, and water quality. It’s also able to augment existing water flow. This allows it to provide a consistent supply, even when levels are low and drought conditions affect a region.

An expert in performing hydrological studies and contracting with mine owners, HCPA possesses the hydrological and engineering know-how to maximize filtration, treatment, and distribution of water resources. Its low-cost treatment and distribution model involves locating, procuring, treating, and distributing water while preserving the environment. The subsidiary can serve a range of applications, including oil and gas, utilities, mining, pipelines, industry, and local municipalities.

HCPA’s patent-pending proprietary water conveyance system is a key component of the subsidiary’s treatment and distribution model, which it plans to implement together with AES, to begin with, by remediating pools of non-potable water. Its recent contract with the Eastern Pennsylvania Coalition for Abandoned Mine Reclamation (“EPCAMR”) to engage the Susquehanna River Basin Commission (“SRBC”) in a study of the Mocanaqua Abandoned Mine Drainage (AMD) Tunnel will serve as a starting point for the new model, proving its efficacy and validity.

Providing off the shelf and custom water treatment solutions, AES is devoted to serving the industrial waste sector. It offers remediation of superfund sites. Also, it can remedy coal ash, acid mine draining, and various other industrial processes. Flowback and produced waters, as well as drill cuttings, can be managed. Specializing in project design and managing strategic partnerships with established water treatment providers, AES can offer performance evaluation and aims to generate market share.

Gilbert is an energy source producer operating in the Marcellus and Utica region. As such, the subsidiary and its competitors represent potential XFUL customers. The market itself is a driver for potential growth of the company and its subsidiaries. Much water is utilized in hydraulic fracturing, including that purchased from public utilities. Flowback and treated wastewater from existing wells are significant. Aside from these water-intensive industrial processes, water use is a major aspect of irrigation, aquaculture, thermoelectric power, mining, and domestic use. In Pennsylvania, thermoelectric power alone consumes 6.43 billion gallons of water per day, and public water supplies use 1.42 billion gallons each day, demonstrating the size of the market XFUL can reach.

For more information, visit the company’s website at www.AmericanEnergy-Inc.com

Let us hear your thoughts: Converde Energy USA, Inc. Message Board

Moving toward offering the very first therapy for treating epidermolysis bullosa (EB), InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) recently announced it has signed an agreement with Pharmaseed Ltd. (http://dtn.fm/o5XNU) to develop a final formulation for INM-750, InMed’s lead compound, which is being developed as a therapy for EB and for other potential dermatological and wound-healing applications.

EB is a group of inherited connective tissue diseases sharing a common manifestation of very fragile skin that is prone to easily blistering or tearing. An orphan disease that currently has no approved treatments and has significant unmet medical need, EB results from a defect in anchoring between the dermis and the epidermis and is most commonly caused by the absence of specific keratins in the skin. In addition to its effects on the skin, EB can also affect bodily systems and internal organs.

InMed’s INM-750 is a proprietary topical product candidate that includes multiple cannabinoids as its active ingredients, which were chosen to modulate keratin levels in EB patients in anticipation of having a disease-modulating effect. A secondary reason for selecting these cannabinoids was to address EB symptoms, including inflammation, wound healing, skin regeneration, itching and pain. In development as a topical application, INM-750 is designed to optimize penetration of the cannabinoids to the skin’s epidermal/dermal junction.

Through the agreement with Pharmaseed, which is the largest GLP-certified preclinical contract research organization in Israel, InMed is taking another step toward moving INM-750 to its first clinical trial. Under the terms of the agreement, Pharmaseed will develop a final formulation for INM-750 for ongoing R&D, including IND-enabling pharmacology and toxicology studies and eventual clinical studies. The contract also includes the development of assay methods for manufacturing, stability, quality assurance and other methods of analysis.

A preclinical-stage biopharmaceutical company, InMed specializes in the research and development of cannabinoid-based prescription drug therapies that utilize novel drug delivery systems. For its product candidates, the company conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities. InMed’s primary value drivers are its proprietary bioinformatics database assessment tool, biosynthesis manufacturing process and drug development programs.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board